These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31149541)

  • 1. Double primary recurrent human epidermal growth factor receptor 2-positive breast cancer and esophageal cancer that responded well to chemotherapy.
    Yokoi S; Maeda H; Nishino T; Togawa T; Iida A; Goi T
    Int Cancer Conf J; 2019 Jan; 8(1):17-23. PubMed ID: 31149541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successfully treated advanced esophageal cancer with left axillary lymph node metastasis and synchronous right breast cancer: a case report.
    Akiyama Y; Iwaya T; Shioi Y; Endo F; Ishida K; Kashiwaba M; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A
    Surg Case Rep; 2015 Dec; 1(1):94. PubMed ID: 26943418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term complete response in supraclavicular lymph node metastases of esophageal cancer using systemic chemotherapy-a case report.
    Zhang S; Shi W
    Int J Clin Exp Pathol; 2019; 12(9):3679-3684. PubMed ID: 31934220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and Emerging Therapies for HER2-Positive Women With Metastatic Breast Cancer.
    Porter K; Rosenzweig MQ
    J Adv Pract Oncol; 2017 Mar; 8(2):164-168. PubMed ID: 29900024
    [No Abstract]   [Full Text] [Related]  

  • 5. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
    Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
    Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
    Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of effective trastuzumab plus gemcitabine therapy for human epidermal growth factor receptor 2-positive breast cancer].
    Yabe N; Murai S; Shimizu H; Kitasato K; Yoshikawa T; Oto I; Nakadai J; Jinno H; Kitagawa Y
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2396-8. PubMed ID: 24394124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer.
    Sugase T; Sugimura K; Kanemura T; Takeoka T; Yamamoto M; Shinno N; Hara H; Omori T; Fujii Y; Mukai Y; Mikamori M; Hasegawa S; Haraguchi N; Akita H; Nishimura J; Wada H; Matsuda C; Yasui M; Miyata H
    Oncology; 2022; 100(12):655-665. PubMed ID: 36198297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of residual metastatic lymph node lesion following definitive chemoradiotherapy for T4 esophageal cancer, successfully treated by outpatient clinic-based sequential chemotherapy with docetaxel followed by S-1].
    Yoneda M; Fujiwara H; Shiozaki A; Komatsu S; Ichikawa D; Okamoto K; Murayama Y; Kuriu Y; Ikoma H; Nakanishi M; Ochiai T; Kokuba Y; Otsuji E
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2397-400. PubMed ID: 22202394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-Term Survival of a Patient with Triple-Negative Breast Cancer with Hormone Receptor Status Conversion between Primary and Metastatic Tumors].
    Hayashi K; Harao M; Ogihara K; Sasaki Y; Nishida S; Shiba S; Sakuragi M; Kitayama J; Sata N
    Gan To Kagaku Ryoho; 2022 Jun; 49(6):697-699. PubMed ID: 35799399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Conversion Therapy for HER2-Positive Metastatic Breast Cancer with Intrathoracic Lymph Node Metastasis].
    Kono H; Maeda H; Yao S; Takahashi M; Yokoi S; Goi T; Imamura Y
    Gan To Kagaku Ryoho; 2020 Jun; 47(6):977-980. PubMed ID: 32541178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU].
    Ehara K; Tsutsumi K; Kinoshita Y; Ueno M; Mine S; Udagawa H
    Gan To Kagaku Ryoho; 2008 Aug; 35(8):1375-8. PubMed ID: 18701852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab in combination with radiotherapy for metastatic esophageal neuroendocrine carcinoma after esophagectomy: a case report.
    Takagi K; Kamada T; Fuse Y; Kai W; Takahashi J; Nakashima K; Nakaseko Y; Suzuki N; Yoshida M; Okada S; Ohdaira H; Suzuki Y
    Surg Case Rep; 2021 Oct; 7(1):221. PubMed ID: 34596772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A Case of Bilateral HER2-Positive Invasive Ductal Carcinoma with Complete Response on One Side with Trastuzumab Deruxtecan].
    Miyazaki S; Iwasaki K; Narita T; Yoneda G; Takei H; Jibiki N
    Gan To Kagaku Ryoho; 2023 Mar; 50(3):327-331. PubMed ID: 36927901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple metastases of human epidermal growth factor receptor 2‑positive, hormone receptor‑positive, pT1a pN0 breast cancer within 1 year after surgery: A case report.
    Suzuki T; Einama T; Takushima M; Araki Y; Wakamatsu K; Kobayashi K; Ohno H; Fukumura-Koga M; Yamasaki T; Ueno H; Tsuda H; Kishi Y
    Oncol Lett; 2024 Aug; 28(2):365. PubMed ID: 38933808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A Case of HER2-Positive Metastatic Breast Cancer Achieved a Complete Response to Paclitaxel and Trastuzumab in Combination with Pertuzumab in Fifth Therapy].
    Mimata A; Yoshitomi S; Morikawa N; Hara K; Tsuji H
    Gan To Kagaku Ryoho; 2021 Feb; 48(2):263-265. PubMed ID: 33597376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case of Brachial Lymph Node Recurrences after the Resection of Locally Advanced Breast Cancer.
    Onishi K; Watanuki R; Yokoe T; Iwatani T; Yamauchi C; Onishi T
    Case Rep Oncol; 2022; 15(2):738-744. PubMed ID: 36157692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).
    Aogi K; Saeki T; Nakamura S; Kashiwaba M; Sato N; Masuda N; Rai Y; Ohno S; Kuroi K; Nishimura R; Miyakoda K; Akiyama F; Kurosumi M; Ikeda T
    Int J Clin Oncol; 2013 Aug; 18(4):598-606. PubMed ID: 22833344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.